Skip to main content
Carotid AtherosclerosisDiagnostics and screeningHealthy volunteersDrugPhase 1

What this study is

: Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis

What's being tested

  • Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)

    Intervention · DRUG

    Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy

  • Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)

    Intervention · DRUG

    Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart

Study details

Sponsor
Washington University School of Medicine
Conditions
Carotid Atherosclerosis
Enrolling
100 people
Starts
2020-10-01
Est. completion
2025-09-01
Design
Open-label, non-randomized, single group, Phase 1
Record
View on ClinicalTrials.gov ↗